source
- GE HealthCare eyes $1 billion purchase of radiopharmaceutical developer Sofie BiosciencesGE HealthCare is reported to be weighing a purchase of Sofie Biosciences, a radiopharmaceutical developer, for as much as $1 billion, according to the Financial Times. Sofie Biosciences, based in…
- AstraZeneca's breast cancer pill camizestrant fails to improve progression-free survival in pivotal SERENA-4 trialAstraZeneca announced that its oral estrogen receptor degrader camizestrant, marketed as Etcamah, did not meet its primary endpoint in the phase III SERENA-4 trial. The study evaluated camizestran…